RxDoctor Payments Data

Kenneth Johnston, MD

Family Medicine · Little Rock, ARNPI 1245224229

Payments from drug & device makers

$9,090in general payments, 2019–2025

Across 637 payments — averaging $14.27 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • GSK$1K
  • Amgen$941
  • Lilly USA, LLC$739
  • Pfizer$639
  • Astellas Pharma US Inc$522
  • plus $3K from 37 others

What the payments were for

  • Food & beverage$9,053100%
  • Education$360%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,090 in reported general payments places this provider in the 90th percentile of 1,347 family medicine providers in Arkansas.

See all family medicine providers in Arkansas

Medicare billing

Part B allowed, 2024
$201,120
Medicare patients
602
Services billed
11,379

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban141$120,840
MounjaroTirzepatide106$117,418
OzempicSemaglutide99$97,255
JardianceEmpagliflozin87$79,328
ArexvyRsvpref3 Antigen/As01e/Pf110$32,257
TrulicityDulaglutide15$25,001
Repatha SureclickEvolocumab39$21,435
Tresiba Flextouch U-200Insulin Degludec14$21,335
LinzessLinaclotide25$20,403
FarxigaDapagliflozin Propanediol25$18,469
Trelegy ElliptaFluticasone/Umeclidin/Vilanter28$18,027
XareltoRivaroxaban30$17,424
ZenpepLipase/Protease/Amylase12$14,332
MyrbetriqMirabegron17$12,373
Raloxifene Hcl259$11,074

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$739$142,419121 claims
PfizerEliquis, Premarin$639$127,225164 claims
Novo NordiskOzempic$360$97,25599 claims
Boehringer IngelheimJardiance$226$79,32887 claims
GSKArexvy, Trelegy Ellipta, Breo Ellipta, Shingrix$1,353$66,383184 claims
MerckBelsomra, Januvia, Janumet, Dulera$399$35,49068 claims
AbbVieLinzess, Synthroid, Fetzima$1,514$34,735122 claims
AstraZenecaFarxiga, Breztri Aerosphere, Symbicort$463$32,61951 claims
Johnson & JohnsonXarelto$15$17,42430 claims
Astellas Pharma US IncMyrbetriq$522$12,37317 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,347 family medicine providers in Arkansas.

Other family medicine in Little Rock

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →